SCHEMBL30289643

SCHEMBL30289643

CC(C)(C)OC(=O)N1CC(OC2CN(C(=O)OCc3ccccc3)C2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HTT P42858 1/20 0.49
CYP2C19 P33261 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PDE4B Q07343 1/20 0.47
PARP1 P09874 1/20 0.47
HTR2C P28335 1/20 0.46
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
STS P08842 1/20 0.46
NAMPT P43490 1/20 0.46
RORC P51449 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26634884 0.93 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL29304070 0.93 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL21820354 0.93 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL29304084 0.91 JAK2 (0.49) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL6095209 0.90 JAK2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL30993456 0.90 JAK2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL31288410 0.90 JAK2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL29304184 0.88 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL30963373 0.88 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL2327412 0.86 MEN1 (0.50) SMN1; SMN2NPC1RAB9AHTTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 EP disclosed
WO-2023049790-A2 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-30 WO disclosed